As Biotechnology businesses, OPKO Health Inc. (NASDAQ:OPK) and BioTime Inc. (NYSEAMERICAN:BTX), are affected by compare. This especially applies to their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health Inc.	1.03B	1.63	298.50M	-0.52	0.00
BioTime Inc.	5.23M	28.46	72.97M	-0.58	0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 provides us the return on assets, net margins and return on equity of both businesses.

	Net Margins	Return on Equity	Return on Assets
OPKO Health Inc.	-28.98%	-16%	-11.4%
BioTime Inc.	-1,395.22%	-54.6%	-51%

Volatility & Risk

OPKO Health Inc. is 102.00% more volatile than S&P 500 because the company has a beta of 2.02. BioTime Inc. on the other hand, has 2.21 beta which makes it 121.00% more volatile compared to S&P 500.

Liquidity

OPKO Health Inc. has a Current Ratio of 0.9 and a Quick Ratio of 0.8. Competitively, BioTime Inc.’s Current Ratio is 8.2 and has 8.2 Quick Ratio. BioTime Inc.’s better ability to pay short and long-term obligations than OPKO Health Inc.

Institutional and Insider Ownership

Institutional investors owned 27.5% of OPKO Health Inc. shares and 44% of BioTime Inc. shares. Insiders owned roughly 5.1% of OPKO Health Inc.’s shares. On the other hand, insiders owned about 5.3% of BioTime Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
OPKO Health Inc.	-11.23%	-13.99%	-43.34%	-19.61%	-36.28%	-32.24%
BioTime Inc.	-9.09%	-18.3%	-27.6%	-25.08%	-29.39%	-20.2%

For the past year OPKO Health Inc. was more bearish than BioTime Inc.

Summary

On 6 of the 10 factors OPKO Health Inc. beats BioTime Inc.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico. The companyÂ’s Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The companyÂ’s pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing TT401, which is in Phase II clinical trials for type 2 diabetes and obesity; TT701, an androgen receptor modulator that is in Phase II clinical trials for androgen deficiency indications; and hGH-CTP, a growth hormone injection that is in Phase III clinical trials. In addition, it engages in developing and commercializing hGH-CTP, a recombinant human growth hormone product that is in Phase III; developing Factor VIIa drug for hemophilia that is in Phase IIa, an NK-1 compound, and drugs for treating asthma and chronic obstructive pulmonary disease; developing and producing specialty active pharmaceutical ingredients; and discovery of drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. Its product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor (BDNF) directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. The company also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer. In addition, it offers liquid biopsy tests for diagnosis of cancer; bone grafting products to treat orthopedic disorders; and mobile health software products. Further, it markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; MalaCards, a human disease database; VarElect, an application for prioritizing gene variants; and GeneAnalytics, a novel gene set analysis tool. Additionally, the company develops and markets Hextend, a blood plasma volume expander used for the treatment of hypovolemia. BioTime, Inc. was founded in 1990 and is based in Alameda, California.